We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Committees Recommend Approval for Reformulated OxyContin
Committees Recommend Approval for Reformulated OxyContin
September 25, 2009
Two FDA advisory committees voted 14–4 with one abstention to recommend approval of Purdue Pharma’s reformulated version of long-acting OxyContin, despite some members’ concerns over the drug’s safety.